TY  - CHAP
M1  - Book, Section
TI  - Chronic Kidney Disease/End Stage Renal Disease
A1  - Burnworth, Melinda J.
A1  - Walton, Ted
A2  - Sutton, S. Scott
PY  - 2020
T2  - McGraw Hill’s NAPLEX® Review Guide, 4e
AB  - Chronic  kidney  disease  (CKD)  is  a  progressive  disease  staged  on  the  patient's  glomerular  filtration  rate  (GFR)  and  presence  of  albuminuria.  The  National  Kidney  Foundation's  Kidney  Disease  Outcomes  Quality  Initiative  (KDOQI)  and  the  global  non-profit  foundation,  Kidney  Disease:  Improving  Global  Outcomes  (KDIGO),  define  CKD  as:  (1)  pathological  abnormalities  or  markers  of  kidney  damage  such  as  proteinuria  present  for  3  months  or  more  with  or  without  a  decreased  GFR,  or  (2)  a  GFR  less  than  60  mL/min/1.73  m2  for  3  months  or  more.  Staging  of  CKD  identifies  patients  at  higher  risk  of  worsening  clinical  manifestations  and  disease  complications.  Stages  are  determined  by  GFR  and  albuminuria  categories.  See  Table  35-1  for  CKD  staged  by  GFR.  Albuminuria  is  categorized  as  A1,  A2,  or  A3  by  urine  albumin-to-creatinine  ratio  (ACR)  as  mg/g  or  urinary  albumin  excretion  rate  (AER)  as  mg/24  hour.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/20
UR  - accesspharmacy.mhmedical.com/content.aspx?aid=1179734699
ER  -